Modified factor VII
AssigneesZymoGenetics, Inc., Novo Nordisk A/S
InventorsKathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
Life of this patent
Estimating the term…
Abstract
The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders, including platelet deposition, vascular thrombosis, ischemic reperfusion, acute closure of a coronary artery, vascular restenosis secondary to balloon angioplasty, endarterectomy, reductive atherectomy, stent placement, laser therapy or rotablation.
Claims15
A method for inhibiting thrombus formation in a patient comprising administering topically to a vascular site susceptible to thrombus formation in the patient a therapeutically effective dose of a composition comprising human Factor VII having at least one covalent modification in its catalytic center, which modification inhibits the ability of the modified Factor VII to activate plasma Factor X or IX.
A method for maintaining or improving vascular patency in a patient comprising administering locally to a vascular site susceptible to decreased patency a therapeutically effective dose of a composition comprising human Factor VII having at least one covalent modification in its catalytic center, which modification inhibits the ability of the modified Factor VII to activate plasma Factor X or IX.
A method for treating acute closure of a coronary artery in an individual, comprising administering to the individual a composition which comprises a pharmacologically acceptable human Factor VII having at least one covalent modification in its catalytic center, which modification inhibits the ability of the modified Factor VII to activate plasma Factor X or IX, in conjunction with tissue plasminogen activator or streptokinase.
Dependencies are inferred from the claim text.